Abiopharma

🔍 HOOLEY JOSEPH L (Director)

Company: IDEXX LABORATORIES INC /DE (IDXX)

Report Date: 2025-09-01

Detailed Transactions and Holdings:

• Acquired 158 shares of Restricted Stock Unit (Derivative)
  Date: 2025-09-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 158.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2, F2
• Acquired 364 shares of Non-Qualified Stock Option (right-to-buy) at $647.09 per share (Derivative)
  Date: 2025-09-01 | Code: A | Expires: 2035-08-31 | equity_swap_involved: 0 | shares_owned_after: 364.00 | transaction_form_type: 4 | Footnotes: F1, F3, F4

Footnotes:

• F1: This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on July 10, 2025 until the 2026 annual meeting of stockholders.
• F2: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock and vest in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier.
• F3: Closing price of Issuer common stock on the Nasdaq Global Select Market on August 29, 2025.
• F4: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier.